Within this framework, glucagon-like peptide-1 receptor agonists (GLP-1RAs), initially developed for the treatment of type 2 diabetes and obesity, have been identified as promising candidates for modulating the neural circuits involved in addiction [5,6,7]. The gene discussed is GLP1R; the disease is obesity due to melanocortin 4 receptor deficiency.